Pregnancy outcome in women with antiphospholipid antibodies: Report on a retrospective study

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 8, 2008, Pages 794-802

  Heilmann, Lothar ^a   Schorch, Martin ^a   Hahn, Thomas ^a   Adasz, Geza ^a   Schilberz, Karin ^a   Adiguzel, Cafer ^b   Fareed, Jawed ^b  

^a Institute of Reproduction   (Germany)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiphospholipid syndrome; Certoparin; Dalteparin; Intravenous immunoglobulins; Low molecular weight heparin; Pregnancy

Indexed keywords

ACETYLSALICYLIC ACID; CERTOPARIN; CORTISONE; DALTEPARIN; HEPARIN CALCIUM; IMMUNOGLOBULIN; PHOSPHOLIPID ANTIBODY;

ABORTION; ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLEEDING; CELL COUNT; DRUG USE; DRUG WITHDRAWAL; FEMALE; FETUS WASTAGE; FLUSHING; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; LIVE BIRTH; MAJOR CLINICAL STUDY; NATURAL KILLER CELL; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; SKIN MANIFESTATION; THIRD TRIMESTER PREGNANCY;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KILLER CELLS, NATURAL; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 60549083116     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0029-1145261     Document Type: Article

References (79)

1. Birdsall MA, Lockwood GM, Ledger WL. Antiphospholipid antibodies in women having in-vitro fertilization. Hum Reprod 1996;11:1185-1189
2. Carp HJA. Antiphospholipid syndrome in pregnancy. Curr Opin Obstet Gynecol 2004;16:129-135
3. Cervera R, Piette JC, Font J, Khamashta MA; for the Euro-Phospholipid project group. Antiphospholipid syndrome. Arthritis Rheum 2002;46:1019-1027
4. Katano K, Aoki A, Sasa H, et al. β 2-glykoprotein1-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Hum Reprod 1996;11:509-512
5. Pattison NS, Chamley LW, McKay EJ, et al. Antiphospholipid-antibodies in pregnancy: prevalence and clinical association. Br J Obstet Gynaecol 1993;100:909-913
6. Schleussner E. Impact of the antiphospholipid syndrome on complications during pregnancy. Transfus Med Hemother 2006;33:486-492
7. Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol 1995;86:555-559
8. Carp HJA. Intravenous immunoglobulin: effect on infertility and recurrent pregnancy loss. Israel Medical Association Journal 2007;9:877-880
9. Clark DA, Coulam CB, Stricker RB. Is intravenous immunoglobulins (IVIG) efficacious in early pregnancy failure? A critical review and metaanalysis for patients who fail in vitro fertilization and embryo transfer(IVF) J Assist Reprod Genet 2006;23:1-13
10. Canesi B, Brucato A. Antiphospholipid antibodies and pregnancy. Haematologica Reports 2005;1:6-12
11. Galli M, Barbui T. Antiphospholipid antibodies and pregnancy. Best Pract Res Clin Haematol 2003;16:211-225
12. Salmon JE, de Groot PG. Pathogenic role of antiphospholipid antibodies. Lupus 2008;17:405-411
13. Kutteh WH. Antiphospholipid-antibody-associated recurrent pregnancy loss. Treatment with heparin and low dose aspirin is superior to low dose aspirin alone. Am J Obstet Gynecol 1996;174:1584-1589
14. Vashisht A, Regan L. Antiphospholipid syndrome in pregnancy - an update. J R Coll Physicians (Edinburg) 2005;35:337-339
15. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 2004;127(suppl 3):627-644
16. Empson M, Lassere M, Craig JC, Scott JR. Recurrent pregnancy loss with antiphospholipid antibody. A systematic review of therapeutic trials. Obstet Gynecol 2002;99:135-144
17. Stephenson MD, Ballem PJ, Tsang P, et al. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular heparin to unfractionated heparin. J Obstet Gynaecol Canada 2004;26:729-734
18. Branch W, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis. Management and controversies. Obstet Gynecol 2003;101:1333-1344
19. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995;74:1185-1190
20. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006;295:1050-1057
21. Lynch AM, Rutledge JH, Stephens JK, et al. Longitudinal measurement of anti-cardiolipin antibodies during normal pregnancy:a prospective study. Lupus 1995;4:365-369
22. Tincani A, Bazzani C, Zingarelli S, Lojacono A. Lupus and the antiphopsholipid syndrome in pregnancy and obstectrics: clinical characteristics, diagnosis, pathogenesis and treatment. Semin Thromb Hemost 2008;34:267-273
23. Pierangeli SS, Chen PP, Raschi E, et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008;34:236-250
24. Ogasawara M, Sasa H, Katano K, et al. Recurrent abortion and moderate or strong antiphospholipid antibody production. Int J Gynaecol Obstet 1998;62:183-188
25. Tincani A, Branch W, Levy RA, et al. Treatment of patients with antiphospholipid syndrome. Lupus 2003;12:524-529
26. Backos M, Rai R, Baxter N. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. Br J Obstet Gynaecol 1999;106:102-107
27. Cowchock S. Prevention of fetal death in the antiphospholipid antibody syndrome. Lupus 1996;5:467-472
28. Clark AL, Branch DW, Silver RM. Pregnancy complicated by the antiphospholipid syndrome: outcomes with intravenous immunoglobulin therapy. Obstet Gynecol 1999;93:437-441
29. Alarcon-Segovia D, Boffa MC, Branch W, et al. Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 2003;12:499-503
30. Greaves M, Cohen H, MacHin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000;109:704-715
31. Chang P, Millar D, Tsang P, et al. Intravenous immunoglobulin in antiphospholipid syndrome and maternal floor infarction when standard treatment fails: a case report. Am J Perinatol 2006;23:125-129
32. Cowchock S. Treatment of antiphospholipid syndrome in pregnancy. Lupus 1998;17:95-97
33. Farquharson RG, Jauniaux E, Exalto N. Updated and revised nomenclature for description of early pregnancy events. Hum Reprod 2005;20:3008-3011
34. Huong DLT, Wechsler B, Bletry O, Vaunthier-Brouzes D, Lefebvre G, Piette J-C. A study of 75 pregnancies in patients with antiphospholipid syndrome. J Rheumatol 2001;28:2025-2030
35. Carp HJA, Asherson RA, Shoenfeld Y. Intravenous immunglobulin in pregnancies complicated by the antiphospholipid syndrome: what is its role. J Clin Rheumatol 2001;7:291-294
36. Perricone C, Carolis CD, Giacomelli R, et al. High levels of NK cells in the peripheral blood of patients affected with antiphospholipid syndrome and recurrent spontaneous abortion: a potential new hypothesis. Rheumatology 2007;46:1574-1578
37. Aoki K, Hayashi Y, Hirao Y, Yagami Y. Specific antiphospholipid antibodies as a predictive variable in patients with recurrent pregnancy loss. Am J Reprod Immunol 1993;29:82-87
38. Emmer PM, Nelen WLDM, Steegers EAP, Hendriks JCM, Veerkoek M, Joosten I. Peripheral natural killer cell cytotoxicity and CD56pos CD16 pos cells increase during early pregnancy in women with a history of recurrent spontaneous abortion. Hum Reprod 2000;15:1163-1169
39. Van den Heuvel MJ, Crystal GP, Hatta K, Han VK, Clark DA. Decline in number of elevated blood CD3+ CD56+ NKT cells in response to intravenous immunoglobulin treatment correlates with successful pregnancy. Am J Reprod Immunol 2007;58:447-459
40. Veenstra van Nieuwenhoven AL, Heinemann MJ, Faas MM. The immunology of successful pregnancy. Hum Reprod Update 2003;9:347-357
41. Beer AE, Kwaak TY, Ruiz JE. Immunophenotypic profiles of peripheral blood lymphocytes in women with recurrent pregnancy loss and infertile women with multiple failed in vitro fertilization cycles. Am J Reprod Immunol 1996;35:376-382
42. Coulam CB, Beaman KD. Reciprocal alteration in circulating TJ6+ CD19+ and TJ6+ CD56+ leukocytes in early pregnancy predict success or miscarriage. Am J Reprod Immunol 1995;34:219-224
43. Kwak-Kim J, Gillman-Sachs A. Clinical implication of natural killer cells and reproduction. Am J Reprod Immunol 2008;59:388-400
44. Vila P, Hernandez MC, Lopez-Fernandez MF. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994;72:209-213
45. Keskin DB, David S, Allan J, et al. TGFβ promotes conversion of CD16+ peripheral blood NK cells into CD16-NK cells with similarities to decidual NK cells. Proc Natl Acad Sci U S A 2007;104:3378-3383
46. Sacks G, Fay L, Smith S, Russell P, Chapman M. NK cells analysis in women with recurrent reproductive failure; there is a clinical correlation between peripheral blood and endometrial biopsy samples. The Royal Australian and New Zeeland College of Obstetricians and Gynecologists 2007;47(Suppl 1):A27-28
47. Varla-Leftherioti M, Spyropoulou-Vlachou M, Niokou D et al. Natural killer (NK) cell receptors repertoire in couples with recurrent spontaneous abortions. Am J Reprod Immunol 2003;49:183-191
48. Varla-Leftherioti M, Spyropoulou-Vlachou M, Keramitsoglou T. Lack of the appropriate natural killer cell inhibitory receptors in women with spontaneous abortion. Hum Immunol 2005;66:65-71
49. Wilson WA, Harris N. Management of antiphospholipid syndrome in pregnancy. In: Carp HJA, ed. Recurrent Pregnancy Loss. London, United Kingdom: Informa Healthcare; 2007:119-125
50. Vacca P, Pietra G, Falco M, et al. Analysis of natural killer cells isolated from human decidua: evidence that 2B4(CD244) functions as an inhibitory receptor and blocks NK-.cell function. Blood 2006;108:4078-4085
51. Yamada H, Shimada S, Kato EH, et al. Decrease in a specific killer cell immunoglobulin-like receptor on peripheral natural killer cells in women with recurrent spontaneous abortion of unexplained etiology. Am J Reprod Immunol 2004;51:241-247
52. Yamada H, Shimada S, Morikawa M, et al. Divergence of natural killer cell receptor and related molecule in the decidua from sporatic miscarriage with normal chromosome karyotype. Mol Hum Reprod 2005;11:451-457
53. Hiby SE, Regan L, Lo W, Farrell L, Carrington M, Moffet A. Association of maternal killer-cell immunoglobulin-like receptor and parental HLA-C genotypes with recurrent miscarriage. Hum Reprod 2008;23:972-976
54. Witt CS, Goodridge J, Gerbase-Delina MG, Daher S, Christiansen FT. Maternal KIR repertoire is not associated with recurrent spontaneous abortion. Hum Reprod 2004;19:2653-2657
55. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Report of an international workshop. Arthritis Rheum 1999;42:1309-1311
56. Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 2000;43:440-443
57. Bertolaccini ML, Khamashta MA. Laboratory diagnosis and management challenges in the antiphospholipid syndrome. Lupus 2006;15:172-178
58. Franklin RD, Hollier N, Kutteh WH. β2-Glycoprotein 1 as a marker of antiphospholipid syndrome in women with recurrent pregnancy loss. Fertil Steril 2000;73:531-535
59. Carmo-Pereira S, Bertolaccini ML, Escudero-Contres A, et al. Value of IgA anticardiolipin and anti-B-2 glycoprotein 1 antibody testing in patients with pregnancy morbidity. Ann Rheum Dis 2003;62:540-543
60. Chong P, Matzner W, Ching W. Correlation between beta-2-glycoprotein antibodies and antiphospholipid antibodies in patients with reproductive failure. Am J Reprod Immunol 1998;40:414-417
61. Kiprov DD, Nachtigall RD, Weavers RC, Jacobson A, Main EK, Garvoy MR. The use of intravenous immunoglobulin in recurrent pregnancy loss associated with combined alloimmune and autoimmune abnormalities. Am J Reprod Immunol 1996;36:228-234
62. Stojanovich L, Mikovic Z, Mandic V, Popvid-Kuzmanovic D. Treatment of antiphospholipid-syndrome in pregnancy with low dose of intravenous immunoglobulin. Isr Med Assoc J 2007;9:555-556
63. Lynch A, Mariar R, Murphy J, et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. Ann Intern Med 1994;120:470-475
64. Kaira S, Tuli A, Goyal U, Choudhary R, Raheja S. Correlation of antiphospholipid antibody IgM with first trimester recurrent abortion. J Anat Soc India 2002;51:10-13
65. Lockwood CJ, Omero R, Feinburg RF, Clyne LP, Coster B, Hobbins JC. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general population. Am J Obstet Gynecol 1989;161:369-373
66. Fialova L, Mikolikova L, Matous-Malbohan I, Benesova O, Zwinger A. Prevalence of various antiphospholipid antibodies in pregnant women. Physiol Res 2000;49:299-305
67. Branch DW, Andres R, Digre KB, Rote NS, Scott JR. The association of antiphospholipid antibodies with severe preeclampsia. Obstet Gynecol 1989;73:541-545
68. Barbui T, Cortelazzo S, Galli M, et al. Antiphospholipid antibodies in early repeated abortions: a case-controlled study. Fertil Steril 1988;50:589-592
69. Soltesz P, Veres K, Lakos G, Kiss E, Muszbek L, Szegedi G. Evaluation of clinical and laboratory features of antiphospholipid syndrome: a retrospective study of 637 patients. Lupus 2003;12:302-307
70. Konova E, Ivanova I, Petrova P, et al. Effect of intravenous gamma-globulin therapy on lymphocyte population in pregnant women with antiphospholipid antibodies. Akush Ginekol (Sofiia) 2004;43:3-10
71. Branch DW, Peacman AM, Druzin M. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The pregnancy loss study group. Am J Obstet Gynecol 2000;182:122-127
72. Vaquero E, Lazzarin N, Valensise H. Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low dose aspirin. Am J Reprod Immunol 2001;45:174-179
73. Valensise H, Vaquero E, de Carolis C. Normal fetal growth in women with antiphospholipid syndrome treated with high dose intravenous immunoglobulin (IVIG). Prenat Diagn 1995;15:97-102
74. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007;109:422-425
75. Wang S, Zhao YR, Jiao YL, et al. Increased activating killer immunoglobulin-like receptor genes and decreased specific HLA-C alleles in couples with recurrent spontaneous abortion. Biochem Biophys Res Commun 2007;360:696-701
76. Caruso AD, Carolis S, Simone N. Antiphospholipid antibodies in obstetrics: new complexities and sites of action. Hum Reprod 1999;5:267-276
77. Perricone C, Carolis CD, Giacomelli R, et al. High levels of NK cells in the peripheral blood of patients affected with antiphospholipid syndrome and recurrent spontaneous abortion: a potential new hypothesis. Rheumatology 2007;46:1574-1578
78. Sargent IL, Borzychowski AM, Redman CWG. NK cells and preeclampsia. J Reprod Immunol 2007;76:40-44
79. Radder CM, Roelen DL, van de Meer-Prind EM, et al. The immunologic profile of infants born after maternal immunoglobulin treatment and intrauterine platelet transfusion for fetal/alloimmune thrombozytopenia. Am J Obstet Gynecol 2004;191:815-820